Epithalamin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-31. Numbers and descriptions here follow the published literature rather than marketing material.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Computed for the free acid of Ala-Glu-Asp-Gly |
| Molecular mass | About 390.35 g/mol | Free peptide; salt forms shift the value |
| Appearance | White to off-white solid | Typical of short peptides after freeze-drying |
| Solubility class | Freely soluble in water | Aqueous buffers are also commonly used |
| Common synonyms | Epitalon, epithalone, AEDG | AEDG is the single-letter sequence |
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
== Malignant neoplasm of lymphatic and hematopoietic tissue (200–208) == 200 Lymphosarcoma and reticulosarcoma 200.0 Reticulosarcoma 200.1 Lymphosarcoma 200.2 Burkitt's tumor or lymphoma 200.3 Marginal zone lymphoma 200.4 Mantle cell lymphoma 200.5 Primary central nervous system lymphoma 200.6 Anaplastic large cell lymphoma 200.7 Large cell lymphoma 200.8 Other named variants of lymphosarcoma and reticulosarcoma 201 Hodgkin's disease 202 Other malignant neoplasms of lymphoid and histiocytic tissue 202.0 Nodular lymphoma 202.1 Mycosis fungoides 202.2 Sézary's disease 202.3 Malignant histiocytosis 202.4 Leukemic reticuloendotheliosis (commonly called hairy cell leukemia) 202.5 Letterer-Siwe disease 202.6 Malignant mast cell tumors 202.7 Peripheral T-cell lymphoma 202.8 Other lymphomas 202.9 Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue 203 Multiple myeloma and immunoproliferative neoplasms 203.0 Multiple myeloma 204 Lymphoid leukemia 204.0 Acute lymphoblastic leukemia 204.1 Chronic lymphocytic leukemia 205 Myeloid leukemia 205.0 Acute myelogenous leukemia 205.1 Chronic myelogenous leukemia 206 Monocytic leukemia 207 Other specified leukemia 207.0 Acute erythremia and erythroleukemia 207.1 Chronic erythremia 207.2 Megakaryocytic leukemia 208 Leukemia of unspecified cell type
Whey protein is a mixture of proteins isolated from whey, the liquid material created as a by-product of cheese production. The proteins consist of α-lactalbumin, β-lactoglobulin, serum albumin and immunoglobulins. Glycomacropeptide also makes up the third largest component but is not a protein. Whey protein is commonly marketed as a protein supplement.
1 March to August 1971 In the DMZ Campaign (1969-71) the 1st Brigade, 5th Infantry Division (Mechanized) assumed responsibility for the defense of the DMZ from the 3rd Marine Division as it withdrew from South Vietnam.
===== Clinical microbiome analyses ===== The use of mNGS to characterize the microbiome has made possible the development of bacterial probiotics to be administrated as pills, for example, as a treatment of Clostridioides difficile-associated diseases.
Sources: en.wikipedia.org
Etorphine (M99) is a semi-synthetic opioid possessing an analgesic potency approximately 1,000–3,000 times that of morphine. It was first prepared in 1960 from oripavine, which does not generally occur in opium poppy extract but rather the related plants Papaver orientale and Papaver bracteatum. It was reproduced in 1963 by a research group at MacFarlan Smith in Edinburgh, led by Kenneth Bentley. It can be produced from thebaine.
Taxifolin (5,7,3',4'-flavan-on-ol), also known as dihydroquercetin, belongs to the subclass flavanonols in the flavonoids, which in turn is a class of polyphenols. It is extracted from plants such as Siberian larch and milk thistle.
In the same year, Hetero expanded its biosimilar portfolio by launching Darbepoetin Alfa and Rituximab- two complex biologics used in the treatment of Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). In 2016, Hetero launched its third biosimilar product, Bevacizumab, a monoclonal antiangiogenic used for the treatment of metastatic colorectal cancer (mCRC). These launches established Hetero as one of the few Indian pharmaceutical companies with a biosimilar business spanning multiple therapeutic indications. In 2017, Hetero received approval from the Drug Controller General of India to produce Velasof, a Sofosbuvir+Velpatasvir fixed dose combination used to treat chronic hepatitis C genotype 1 to 6. The product was launched under a non-exclusive licensing agreement with Gilead Sciences. In 2018, Hetero’s European subsidiary, Amarox Pharma, acquired Tarbis Farma S.L., a Spanish pharmaceutical distribution company, strengthening Hetero’s stand in the European market as they expanded into the retail and hospital pharmacy chains.
SPR curves usually show a strong minimum. With the use of a combined chromium-gold film or other carefully chosen material combinations a sharp resonance maximum can be observed when exciting a surface plasmon in the Kretschmann configuration. This may be useful in sensors applications where a strong and sharp resonance above noise is required and less heat is desired at the surface.
The toxic action of mHTT may manifest and produce the HD pathology through multiple cellular changes. In its mutant (polyglutamine expanded) form, the protein is more prone to cleavage that creates shorter fragments containing the polyglutamine expansion. These protein fragments have a propensity to undergo misfolding and aggregation, yielding fibrillar aggregates in which non-native polyglutamine β-strands from multiple proteins are bonded together by hydrogen bonds. These aggregates share the same fundamental cross-beta amyloid architecture seen in other protein deposition diseases. The aggregates are covered on their surface with a 'fuzzy coat' that contains non-polyglutamine parts of the protein, as illustrated in a published structural model shown above. Over time, the aggregates accumulate to form inclusion bodies within cells, ultimately interfering with neuronal function. Inclusion bodies have been found in both the cell nucleus and cytoplasm. Inclusion bodies in cells of the brain are one of the earliest pathological changes, and some experiments have found that they can be toxic for the cell, but other experiments have shown that they may form as part of the body's defense mechanism and help protect cells. Several pathways by which mHTT may cause cell death have been identified.
Sources: en.wikipedia.org
== Research == Other related drugs under development by Helus Pharma (formerly Cybin) include the deuterated phenethylamine HLP005 (CYB005) and the deuterated tryptamines deupsilocin (HLP003; CYB003) and deudimethyltryptamine (HLP004; CYB004).
Neurotransmitters are generally stored in synaptic vesicles, clustered close to the cell membrane at the axon terminal of the presynaptic neuron. However, some neurotransmitters, like the metabolic gases carbon monoxide and nitric oxide, are synthesized and released immediately following an action potential without ever being stored in vesicles.
==== Binding RuBP ==== Carbamylation of the ε-amino group of Lys210 is stabilized by coordination with the Mg2+. This reaction involves binding of the carboxylate termini of Asp203 and Glu204 to the Mg2+ ion. The substrate RuBP binds Mg2+ displacing two of the three aquo ligands.
== Formation and maintenance == The acidic pH at the skin's surface is mainly maintained by free amino acids and α-hydroxy acids (lactic acids) excreted from sweat; free fatty acids and amino acids from sebum; and urocanic acid and pyroglutamic acid.
Sources: en.wikipedia.org
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.
Epitalon and epithalon both circulate, and the difference reflects transliteration of a name coined in Russian-language publications. Reference to the extract it derives from, epithalamin, explains the shared stem. Databases and suppliers are inconsistent, so a search for one spelling alone may miss relevant entries.
No. Epithalamin is a multi-component preparation obtained from pineal tissue, and its exact composition is not fully characterised. Epitalon is a single defined tetrapeptide described as a short synthetic counterpart of that extract, so the two are related in origin but not interchangeable in identity.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.